IRIS - Res&Arch Institutional Research Information System - Research & Archive

MORETTI, Sonia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.150
EU - Europa 1.084
AS - Asia 217
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 1
Totale 2.457
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.149
UA - Ucraina 277
SE - Svezia 192
IE - Irlanda 178
FR - Francia 119
IT - Italia 101
HK - Hong Kong 88
VN - Vietnam 66
DE - Germania 54
FI - Finlandia 47
CN - Cina 34
RU - Federazione Russa 31
GB - Regno Unito 26
KR - Corea 19
BE - Belgio 14
RO - Romania 12
CH - Svizzera 10
AT - Austria 5
EU - Europa 5
NL - Olanda 5
PL - Polonia 4
TR - Turchia 4
BG - Bulgaria 3
GR - Grecia 3
LB - Libano 3
CZ - Repubblica Ceca 2
SG - Singapore 2
BR - Brasile 1
MX - Messico 1
RS - Serbia 1
UZ - Uzbekistan 1
Totale 2.457
Salva come PNG Salva come JPEG
Città #
Chandler 276
Dublin 178
Jacksonville 152
San Mateo 100
Hong Kong 88
Ann Arbor 69
Dong Ket 66
Medford 51
Princeton 49
Altamura 43
Wilmington 43
Andover 33
Lawrence 31
Beijing 26
Perugia 22
Redmond 19
Woodbridge 16
Brussels 14
Auburn Hills 13
Boardman 13
Ashburn 12
Bucharest 12
Falls Church 10
Saint Petersburg 8
Norwalk 7
Redwood City 6
Shanghai 6
Den Haag 4
Izmir 4
Lausanne 4
Los Angeles 4
New York 4
San Paolo di Civitate 4
Chicago 3
Des Moines 3
Assisi 2
Edinburgh 2
Fremont 2
Guangzhou 2
Ivrea 2
Moscow 2
Mountain View 2
Rome 2
Singapore 2
Stockholm 2
Tappahannock 2
Anguillara Sabazia 1
Belgrade 1
Biel/Bienne 1
Buffalo 1
Cuauhtémoc 1
Formigine 1
Frankfurt Am Main 1
Helsinki 1
Jesi 1
Kiev 1
Lastra a Signa 1
Napoli 1
Paris 1
Philadelphia 1
Prague 1
Raleigh 1
Ravenna 1
Reims 1
San Jose 1
Simi Valley 1
Sovicille 1
São Paulo 1
Temù 1
Vienna 1
Warsaw 1
Totale 1.440
Salva come PNG Salva come JPEG
Nome #
Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif 96
Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF). 90
Search of ret/ptc rearrangement and braf and ras mutations in a umbrian papillary thyroid carcinoma cohort showed high prevalence of braf mutation and allowed to detect a new mutation of braf oncoprotein 80
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. 80
Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation 80
Etiopatogenesi dei carcinomi della tiroide che originano dall’epitelio follicolare 79
Medicina molecolare in chirurgia della tiroide 74
Analisi del proteoma di carcinomi papillari della tiroide positivi per la mutazione BRAFV600E 73
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism 72
Analisi del meccanismo dominante inibitorio esercitato in cis dalle mutazioni inattivanti D594V e G596R sulla mutazione attivante di BRAF V600E 71
BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. 71
Caratterizzazione biochimica e molecolare della nuova mutazione BRAFV599Ins recentemente individuata in un carcinoma papillare della tiroide 67
Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. 65
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors 62
Molecular dynamic simulations of the catalytic domain of BRAF in response to activating and inactivating mutations 60
Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. 58
Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer 58
Le sostituzioni aminoacidiche G596R e D594V hanno un effetto inibitorio dominante sulla funzione della mutazione V600E di BRAF 56
Identification of differentially expressed proteins in papillary thyroid carcinomas with V600E mutation of BRAF 56
Search of RET/PTC rearrangement and BRAF and RAS mutations in a umbrian papillary thyroid carcinoma cohort showed high prevalence of BRAF mutation and allowed to detect a new mutation of BRAF oncoprotein 53
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 53
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. 53
Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation 52
Proteomic analysis of papillary thyroid carcinoma reveals demodulation of mechanisms regulating cell proliferation, susceptibility to oxidative stress and cellular aggregation 50
INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IS UPREGULATED IN THYROID CARCINOMA AND DRIVES THE DEVELOPMENT OF AN IMMUNOSUPPRESSANT TUMOR MICROENVIRONMENT. 47
Braf mutation testing in fnac samples increases accuracy of thyroid cytology in a region of high braf mutation prevalence 46
Synthesis of phosphatidylserine by base exchange in rat cerebellum and cortex 46
Anti-htert sirna-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft 46
Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens 45
Molecular dynamic simulation of the catalytic domain of BRAF in response to activating and inactivating mutation 44
Caratteristiche genetiche di una coorte di carcinomi papillari della tiroide raccolta in Umbria e loro significato clinico 43
Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells 41
Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma 40
Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. 40
Clinical prognosis in BRAF-mutated PTC 40
Oncogeni e chirurgia della tiroide 39
Sunitinib inhibits the growth of thyroid tumor xenografts in mice by acting primarily on tumor angiogenesis 39
Signal transducer and activator of transcription 1 plays a pivotal role in RET/PTC3 oncogene-induced expression of indoleamine 2,3-dioxygenase 1 38
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 37
Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. 36
Germline BRAF mutations in Noonan, LEOPARD and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum 35
Targeted molecular therapies in thyroid carcinoma. 34
Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway 33
EFFETTO DI DUE INIBITORI CHINASICI IN LINEE CELLULARI DI CARCINOMA TIROIDEO: STUDI IN VITRO E IN VIVO 33
L’INIBIZIONE DI IDO1 (INDOLEAMMINA 2,3-DIOSSIGENASI 1) RIDUCE LA PROLIFERAZIONE DELLE CELLULE FTC133 30
RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response 29
Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation 29
Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer. 29
Inactivating D594V and G596R amino acid substitutions have a dominant inhibitory effect on the V600E activating mutation of BRAF. 27
Totale 2.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.344
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.344
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20199 0 0 0 0 0 0 0 0 0 0 7 2
2019/2020356 43 9 45 6 46 26 46 22 44 36 6 27
2020/2021564 6 40 27 46 136 41 43 14 62 22 51 76
2021/2022446 16 74 10 43 9 3 7 145 2 23 44 70
2022/2023740 61 147 7 77 62 68 0 40 246 1 26 5
2023/2024192 24 32 9 5 3 2 43 18 49 7 0 0
Totale 2.555